Lundbeck A/S third quarter revenue increases 7% to DKK 3,619 million

Danish-based H. Lundbeck A/S, a pharmaceutical company specialized in central nervous system (CNS) disorders, reports third quarter revenue of DKK 3,619 million, an increase of 7% compared to the third quarter results of 2009.

Profit from operations (EBIT) was DKK 846 million, an increase of 8% compared to the same period last year. The EBIT margin for the quarter was 23.4%. Continued strong growth in key products Cipralex®, Ebixa® and Azilect®, growing 11%, 9% and 28% respectively. Available video includes Lundbeck headquarters shot and general views of laboratories.

SOURCE thenewsmarket.com

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Researchers may have discovered the key to treating inflammatory diseases